KPC Pharmaceuticals' Novel Nanotechnology-Based Anti-Cancer Drug Receives FDA Approval for Clinical Trials
Pfizer
Pharmaceutical R&D Developer
[2019.05.16/R&D NEWS]Pfizer’s Abrocitinib Succeeds in First Global Phase III Trial for Atopic Dermatitis;Visual Acuity Improved by 3 Lines! GenSight’s Ophthalmic Gene Therapy Phase III Clinical Data at 96 Weeks Announced;Kunming Pharmaceutical Group’s Novel Nanotechnology-Based Anti-Cancer Drug Receives FDA Approval for Clinical Trials; Reduces Risk of Disease Progression and Death by 67% | AbbVie’s Blockbuster Therapy Approved for First-Line Treatment of Leukemia; Accelerating Development of Bispecific Antibodies | F-Star Updates Collaboration Agreement with Merck KGaA, Germany...
We focus on the latest developments in pharmaceutical R&D, providing timely and accurate information for researchers.(Click the title to read the full article)
[Drug Development]
Pfizer’s Abrocitinib Achieves Success in First Global Phase III Trial for Atopic Dermatitis
On the 15th, Pfizer announced that its JAK1 inhibitor abrocitinib achieved positive top-line results in a Phase III study conducted in patients aged 12 years and older with moderate-to-severe atopic dermatitis. This study also marks the first clinical trial of abrocitinib’s global development program for efficacy and safety in atopic dermatitis (JADE).
GenSight Biologics recently announced the initial 96-week data from the Phase III clinical trial REVERSE, evaluating its lead candidate drug GS010 for the treatment of Leber hereditary optic neuropathy (LHON). The study enrolled 37 patients with LHON who had experienced vision loss due to the 11778-ND4 mutation within 6 to 12 months prior to initiating study treatment.
[Drug Approval]
Recently, Kunming Pharmaceutical Group announced that it had received notice from its invested company, CPI, stating that the latter had received a letter from the U.S. Food and Drug Administration (FDA) approving clinical trials of CPI-200 (an anticancer drug based on novel nanotechnology) for the treatment of advanced solid tumors.
Merck and Pfizer recently announced jointly that the FDA has approved a new indication for the PD-L1 tumor immunotherapy Bavencio, namely in combination with the targeted anticancer drug Inlyta as first-line treatment for patients with advanced renal cell carcinoma. This approval makes Bavencio the first anti-PD-L1 therapy to be part of a combination regimen for treating advanced RCC, and simultaneously triggers a milestone payment of €35 million from Pfizer to Merck.
AbbVie Announces FDA Approval of Venclexta, a Blockbuster Anti-Cancer Drug Co-Developed with Roche, in Combination with Gazyva as a First-Line Treatment for Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This is a Non-Chemotherapy Combination Regimen. The FDA Evaluated the Supplemental New Drug Application Through the Real-Time Oncology Review Program and Approved It Two Months After Acceptance.
[R&D Collaboration]
$1 Billion to Develop Protein Degradation Therapies: Vertex and Kymera Reach R&D Collaboration
Vertex Pharmaceuticals and Kymera Therapeutics Announce Four-Year R&D Collaboration to Co-Develop Small-Molecule Protein Degraders Targeting Multiple ProteinsVertex Pharmaceuticals and Kymera Therapeutics have announced a four-year research and development agreement to jointly develop small-molecule protein degraders targeting multiple proteins. This collaboration will combine Kymera’s expertise in targeted protein degradation with Vertex’s scientific, clinical, and regulatory capabilities in developing first-in-class therapies.
Emerging biotechnology company F-star recently announced an amendment to its development agreement with Merck for bispecific tumor immunotherapy antibodies, granting F-star full development rights to the investigational drug FS118.
[Latest Research]
Amyloid plaques are clumps of protein fragments in the brains of Alzheimer’s patients that can disrupt neural connections. To identify these protein fragments in a manner analogous to how Facebook recognizes faces from captured images, a collaborative team of scientists from the University of California, Davis, and the University of California, San Francisco, developed machine learning tools capable of rapidly “detecting” the presence of amyloid plaques in brain tissue samples.
Scientists Identify Potential Therapeutic Targets for Metastatic Prostate Cancer
Scientists from institutions including Weill Cornell Medicine have discovered that treating prostate cancer with drugs targeting the PHLPP2 protein may inhibit the spread of cancer cells to other organs in the body. Inhibiting PHLPP2 may reduce levels of MYC, an oncogenic protein that drives multiple types of cancer and is currently not targetable by conventional drug therapies.
New Research Advances Genetic Studies of Cancer Cells
According to a recent study, a novel method for the complete isolation of cancer cells from blood samples enables comprehensive genetic analysis of these cells, thereby assisting physicians in more effectively targeting tumors and monitoring therapeutic responses.
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.